Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

ll, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

Alternatively, the live webcast of the conference call can be accessed via ViroPharma's website at http://www.viropharma.com.  Windows Media or Real Player will be needed to access the webcast.  An audio archive will be available at the same address until March 11, 2011.

About ViroPharma IncorporatedViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sectio
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
(Date:6/30/2015)... R-Japan Co.,Ltd. obtained the license of cell processing ... from the Ministry of Health, Labour and Welfare Kinki Bureau ... The fact that R- Japan received ... Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, 2015 ... stem cell manufacturing service to medical institutions. As of November ...
(Date:6/30/2015)...  NASA astronaut Kjell Lindgren , who is making ... mission to the International Space Station , will be ... EDT Tuesday, July 7. Lindgren will participate from ... Russia . The interviews will be preceded at 7:30 ... training. To schedule an interview, media must contact ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... that does not sacrifice selectivity to achieve faster flow rates in comparison to ... pores with significant open space to allow easy liquid flow while trapping particulates ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... More than a third,of the people who ... about the,company,s prescription savings programs learned of the ... year-long survey of more than 12,000,patients., The ... who called,AstraZeneca,s information center regarding prescription savings programs,said ...
... Solid Financial Performance While Building for the Future, ... ) today reported strong sales and profit growth in ... and clinical,programs., Revenue increased 25 percent to approximately ... The increase was driven by,growth across all areas of ...
... the past two decades,stem cell transplantation has evolved ... a viable option for patients with hematologic (blood),malignancies ... the Adult Blood and Marrow Stem Cell Transplantation ... Center are,responsible for many of the innovations and ...
Cached Biology Technology:AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 2AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 3Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants 2Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants 3Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants 4
(Date:6/16/2015)... CITY , June 16, 2015 /CNW Telbec/ ... their partnership centralized around the incorporation of handyem,s ... point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented model ... BIO International Conference at the Pennsylvania ... from June 15 th to 18 ...
(Date:6/15/2015)... 2015 A new report [ ... majority of US consumers using mobile banking applications want their ... fingerprint and voiceprint, instead of having to prove who they ... " Mobile Identity   -   The Fusion of Financial ... now the primary channel used by Gen X and Gen ...
(Date:6/9/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... will be providing demonstrations of its iMedNet ... Information Association (DIA) Annual Meeting in Washington ... include previews of many exciting new enhancements that will ... 2015 Feature 1 Release. MedNet ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... , It is well established that exposure to ionizing ... that cause cells to turn cancerous. Now a new ... Energy,s Lawrence Berkeley National Laboratory (Berkeley Lab) has revealed ... Working with cultures of human breast cells, the researchers ...
... Invasive species, toxic chemical contamination and the safety of ... addressed by researchers and government at a major conference on ... from Monday, May 17 to Friday, May 21. ... the Great Lakes to U.S. Environmental Protection Agency Administrator Lisa ...
... research from North Carolina State University is now giving forensic ... the remains of children, and may contribute to resolving missing-persons ... key step in solving crimes, but traditionally it has been ... "The key finding in our research is that children,s faces ...
Cached Biology News:Study raises new concerns about radiation and breast cancer 2Study raises new concerns about radiation and breast cancer 3New forensics research will help identify remains of children 2
... ViaSure Kit is used in conjunction with the ... cells automatically. The ViaSure Staining Reagent uses ... Acridine Orange and Ethidium Bromide to identify live ... while the EasyCount Slide 6 Multi-well Slide ...
... Kit provides a powerful yet simple technology ... acids. The kit provides the heterobifunctional linkers ... quantifying conjugation efficiencies. It enables conjugation of ... other tags with a variety of proteins. ...
... Pierce offers maleimide activated carrier ... hapten-carrier conjugates. Imject Maleimide Activated Carrier ... have been preactivated with a heterobifunctional ... a stable, sulfhydryl-reactive carrier protein. ...
...
Biology Products: